September 23, 2021
InSysBio announces its participation in SITC’s 36th Annual Meeting & Pre-Conference Programs (the Society for Immunotherapy of Cancer) which to be held November 10th to 14th, 2021 in person in Washington, DC, and virtually. InSysBio expert modeler Oleg Demin Jr and his student Elena Vasileva are going to present a poster:
Poster Hall
11/12/2021 - 11/14/2021, 7:00 am - 5:00 pm
Oleg Demin Jr comments on the poster, “This poster presents part of the work done in the framework of the master thesis. She defended her master thesis and graduated from Lomonosov Moscow State University (MSU) a few months ago. Her PK/PD model describes ALX148 (evorpacept), a CD47 blocker developed by ALX Oncology, and was used to select the RP2D. Very nice work! It is always great to be involved in the training of students by InSysBio”.
Follow our presenters!
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | September 2017 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
| ||||
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
|
11
|
12
|
13
|
14
|
15
|
16
|
17
|
|
18
|
19
|
20
|
21
|
22
|
23
|
24
|
|
25
|
26
|
27
|
28
1.
28 Sep 2017 19:27
Computer model showed an optimal anti-amyloid treatment
Moscow, Russia, September 28, 2017. One must activate amyloid degradation as soon as possible to prevent the appearance of the protein plaques in brain under Alzheimer’s conditions. This conclusion was reached by scientists from the biotechnology company InSysBio, who created the first computer model of the disease. The final part of the work has been recently published in CPT: Pharmacometrics & Systems Pharmacology.
|
29
|
30
| |
Thank you for your message! We will get back to you shortly.
